HIV resistance and the developing world.
Rollout of antiretroviral therapy (ART) in resource-limited countries has been identified as a global public health priority. Human immunodeficiency virus (HIV) treatment in the industrialised world is routinely accompanied by regular virological monitoring. By contrast, the implementation of ART in resource-limited settings requires use of standard first- and second-line therapy. One major consequence is the likely emergence of high-level resistance during first-line therapy since most people will stay on a virologically failing regimen for longer periods, potentially compromising the efficacy of second-line therapy. The evidence regarding resistance to triple-drug ART relates to the time at which virological failure occurs in populations from developed countries, with little data from resource-poor contexts where monitoring strategies, HIV subtypes and drug combinations are likely to differ.
Gupta
Ravindra Kumar
RK
Department of Infectious Diseases, John Radcliffe Hospital, Oxford, UK. Rgupta2@nhs.net
Pillay
Deenan
D
D019380:Anti-HIV Agents / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D003906:Developing Countries / Q000191:economics; D024882:Drug Resistance, Viral; D014644:Genetic Variation; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000382:microbiology*; D006801:Humans; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents